Innovent Biologics (HKG:1801) terminated its agreement to issue and sell over 12.8 million new series Pre-A preferred shares of Fortvita Biologics to Lostrancos Ventures following the feedback from its shareholders, a Sunday Hong Kong bourse filing said.
The company had agreed to issue and sell the said shares to the purchaser for $20.5 million on Oct. 25 in order to increase its international business.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments